Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image


Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days


Last updated: December 6, 2019

Summarytoggle arrow icon

Opioids are a group of endogenous and exogenous substances that act on μ-, κ-, and δ-receptors in the CNS and the gastrointestinal tract. All opioids share crucial chemical and pharmacologic properties with morphine. Opioids provide effective analgesia and are used to treat severe acute or chronic pain. They also cause sedation and constipation, which can be used therapeutically. Additionally, opioids reduce coughing. Other effects include strong euphoria (which can quickly lead to addiction) and respiratory depression. Acute opioid intoxication is a potentially life-threatening condition that typically causes altered mental status, severe respiratory depression, and miosis. Treatment of acute opioid intoxication requires emergency measures and administration of an opioid receptor antagonist (e.g., naloxone).


Production of endogenous opioids

Proopiomelanocortin (POMC) is the precursor molecule for different peptide hormones, including:

Opioid receptors

Receptor affinity, intrinsic activity, and ceiling effect

(Relative) analgesic potency


Pain management

Acute pain and sedation

Chronic pain

Pain management outside of emergency medicine or anesthesiology should generally be approached according to the WHO analgesic ladder.

  • General approach
    • Only consider opioids if other pharmacologic and nonpharmacologic measures have not achieved sufficient pain relief
    • Evaluate patients for risk factors of opioid dependency
    • Initiate treatment on a trial basis with regular monitoring and adjustments
    • Opioid-naive patients should receive immediate-release/short-acting formulations
    • Avoid simultaneous prescription of benzodiazepines
  • Common uses
    • Acute exacerbations of chronic pain (e.g., cancer breakthrough pain): e.g., fentanyl sublingual tablets
    • Chronic pain syndromes (e.g., cancer pain, compression fractures of the spine): e.g., fentanyl (also available as a transdermal patch ), morphine (also available as an intrathecal pump system)


Avoid long-term IV opioid administration since this can lead to rapidly acquired opioid tolerance and, ultimately, dependence!

Opioid intoxication

Altered mental status, respiratory depression, and miosis are the classic triad of opioid intoxication! However, the absence of miosis does not rule out opioid intoxication!

Naloxone has a dose-dependent duration of action (shorter than most opioids). Its quick metabolization can, therefore, lead to a renewed effect of opioids!

Opioid withdrawal


Opioid withdrawal causes severe discomfort, but is not life threatening!

Neonatal abstinence syndrome


Exact contraindications may vary depending on the specific substance, dosage, formulation, and route of application. The contraindications listed below apply to most opioids, however.


We list the most important contraindications. The selection is not exhaustive.

Opioids for pain management

Opioid Route of application and corresponding analgesic potency Duration of action

Additional characteristics

  • Oral: 1
  • Parenteral: 1
  • 3–6 hours
  • 3–6 hours


  • Parenteral: 5
  • 3–4 hours
  • < 1
  • 4–6 hours


  • Oral: 0.1
  • Parenteral: 0.13
  • 2–4 hours
  • Oral: 0.15
  • Parenteral: 0.08–0.1
  • 4–6 hours
  • Parenteral: 0.2–0.33
  • 3–4 hours
  • Oral: variable
  • Parenteral: variable
  • 4-8 hours
  • Primarily used in treating opioid withdrawal
  • Duration of action is shorter than half-life → risk of accumulation with repeated dosing
  • Should not be given to opioid-naive patients and only be prescribed by doctors experienced in opioid administration
  • Parenteral: 33
  • 4–8 hours
  • Parenteral: 100
  • 1-1.5 hours
  • Lead substance for analgesia in anesthesiology
  • Strong lipophilia
    • Rapid onset and penetration into the CNS
    • Continuous administration leads to significant accumulation.
  • Additional form of application: fentanyl patch for the treatment of chronic pain

Other opioids


Opioid receptor antagonists bind to the opioid receptors but do not trigger the molecular effects that opioid receptor agonists do. Antagonists that have a high affinity to the opioid receptors (naloxone, naltrexone) can displace opioids from the receptors and may, therefore, be used as antidotes in acute opioid intoxication.

  • Naloxone: rapid onset, short duration (1–2 hours) → preferred for treatment of acute opioid intoxication
  • Naltrexone: long duration (24–48 hours) → used for withdrawal treatment after acute detoxification

Do not administer mild and strong opioids simultaneously!

Buprenorphine is difficult to antagonize with naloxone or naltrexone due to its extremely high receptor affinity!

The effects and side effects of opioids depend on the relative binding affinity to the different opioid receptors and on their effects on other neurotransmitter systems. Although opioids are mainly administered as analgesics, they are also used as sedatives, antidiarrheals, and antitussives.

Therapeutic effects Side effects
μ-opioid receptor agonism
  • Strong analgesia
  • Slowed gastrointestinal transit
  • Respiratory depression with subsequent rise in CO2 (and possibly ICP)
  • Constipation
  • Miosis
  • Bradycardia
  • Strong addictive potential
  • Euphoria
  • Sphincter of oddi dysfunction
δ-opioid receptor agonism
  • Respiratory depression
  • Tolerance
  • Strong addictive potential
κ-opioid receptor agonism
  • Analgesia
  • Sedation
  • Slowed gastrointestinal transit

Clinically relevant respiratory depression is unlikely in the treatment of chronic pain!

Although the sedative, orthostatic, and emetic side effects diminish with progressing opioid treatment, miosis, and constipation persist!
Peripherally acting μ-opioid receptor antagonists antagonize μ-opioid receptors outside of the CNS (e.g., in the gastrointestinal tract) and are used to treat opioid-induced constipation. Examples include methylnaltrexone, naloxegol, alvimopan, and naldemedine.


  1. Equianalgesic Dosing of Opioids for Pain Management .
  2. Opioid Potency Comparison. http://www.emedicinehealth.com/opioid_potency_comparison/article_em.htm. Updated: May 11, 2016. Accessed: February 20, 2017.
  3. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain, Appendix B-8: Opioid Conversion and Brand Availability in Canada.
  4. Kishner S. Opioid Equivalents and Conversions. Opioid Equivalents and Conversions. New York, NY: WebMD. http://emedicine.medscape.com/article/2138678-overview. Updated: April 10, 2016. Accessed: February 20, 2017.
  5. Tramadol. http://fpnotebook.com/Pharm/Analgesic/Trmdl.htm. Updated: February 5, 2017. Accessed: February 20, 2017.
  6. Meperidine. http://www.fpnotebook.com/pharm/analgesic/Mprdn.htm. Updated: February 5, 2017. Accessed: February 20, 2017.
  7. Wanke CA. Approach to the adult with acute diarrhea in resource-rich settings. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/approach-to-the-adult-with-acute-diarrhea-in-resource-rich-settings.Last updated: June 30, 2016. Accessed: February 20, 2017.
  8. Taylora CP, Traynelisb SF, Siffertc J, Popec LE, Matsumotod RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol. Ther. 2016; 164 : p.170–182. doi: 10.1016/j.pharmthera.2016.04.010 . | Open in Read by QxMD
  9. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995; 274 (3): p.1263-1270.
  10. Methadone Hydrochloride (marketed as Dolophine) Information. https://www.fda.gov/Drugs/DrugSafety/ucm142827.htm. Updated: July 10, 2015. Accessed: October 10, 2017.
  11. Katzung BG, Masters S, Trevor A. Basic and Clinical Pharmacology 12/E. McGraw Hill Professional ; 2012
  12. Freye E, Levy JV. Opioids in Medicine: A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States. Springer ; 2008
  13. Swegle JM, Logemann C. Management of Common Opioid-Induced Adverse Effects. Am Fam Physician. 2006; 74 (8): p.1347-1354.
  14. Portenoy RK, Mehta Z, Ahmed E. Cancer pain management with opioids: Prevention and management of side effects. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/cancer-pain-management-with-opioids-prevention-and-management-of-side-effects.Last updated: January 27, 2017. Accessed: February 20, 2017.
  15. Stolbach A, Hoffman RS. Acute opioid intoxication in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/acute-opioid-intoxication-in-adults.Last updated: January 25, 2016. Accessed: February 20, 2017.
  16. Benyamin R, Trescot AM, Datta S, et al. Opioid Complications and Side Effects. Pain Physician. 2008 : p.S105-S120.
  17. CDC Guideline for Prescribing Opioids for Chronic Pain. https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. Updated: March 15, 2016. Accessed: February 20, 2017.
  18. Gupta A, Rosenquist R. Use of opioids in the management of chronic non-cancer pain. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/use-of-opioids-in-the-management-of-chronic-non-cancer-pain.Last updated: January 10, 2017. Accessed: February 20, 2017.
  19. Portenoy RK, Mehta Z, Ahmed E. Cancer pain management with opioids: Optimizing analgesia. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia.Last updated: December 15, 2017. Accessed: February 20, 2017.
  20. Singh MK. Chronic Pain Syndrome. Chronic Pain Syndrome. New York, NY: WebMD. http://emedicine.medscape.com/article/310834. Updated: January 24, 2017. Accessed: February 20, 2017.
  21. Berland D, Rodgers P. Rational Use of Opioids for Management of Chronic Nonterminal Pain. Am Fam Physician. 2012; 86 (3): p.252-258.
  22. Babb M, Koren G, Einarson A. Treating pain during pregnancy. Can Fam Physician. 2010; 56 (1): p.25, 27.
  23. UpToDate, Lexicomp, Inc. Morphine: Drug information. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/morphine-drug-information?source=preview&search=morphine&anchor=F8776704#F8776704.Last updated: February 20, 2017. Accessed: February 20, 2017.
  24. Le T, Bhushan V. First Aid for the USMLE Step 1 2015. McGraw-Hill Education ; 2014
  25. Ghelardini C, Di cesare mannelli L, Bianchi E. The pharmacological basis of opioids. Clin Cases Miner Bone Metab. 2015; 12 (3): p.219-221. doi: 10.11138/ccmbm/2015.12.3.219 . | Open in Read by QxMD
  26. Le T, Bhushan V, Sochat M, Chavda Y. First Aid for the USMLE Step 1 2017. McGraw-Hill Education ; 2017
  27. Stephens E. Opioid Toxicity. Opioid Toxicity. New York, NY: WebMD. http://emedicine.medscape.com/article/815784. Updated: December 19, 2016. Accessed: February 20, 2017.
  28. Bhardwaj H, Bhardwaj B, Awab A. Revisiting opioid overdose induced acute respiratory distress syndrome. Indian J Crit Care Med. 2014; 18 (2): p.119-120. doi: 10.4103/0972-5229.126095 . | Open in Read by QxMD
  29. Sevarino K. Opioid withdrawal: Clinical manifestations, course, assessment, and diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/opioid-withdrawal-clinical-manifestations-course-assessment-and-diagnosis.Last updated: February 1, 2016. Accessed: February 20, 2017.
  30. Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/medically-supervised-opioid-withdrawal-during-treatment-for-addiction.Last updated: August 29, 2016. Accessed: February 20, 2017.
  31. Jansson LM. Neonatal abstinence syndrome. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/neonatal-abstinence-syndrome.Last updated: August 31, 2016. Accessed: February 20, 2017.
  32. Hamdan AH. Neonatal Abstinence Syndrome. Neonatal Abstinence Syndrome. New York, NY: WebMD. http://emedicine.medscape.com/article/978763. Updated: November 27, 2016. Accessed: February 20, 2017.
  33. Broome L, So T-Y. Neonatal abstinence syndrome: the use of clonidine as a treatment option. NeoReviews. 2011; 12 (10): p.e575-e584. doi: 10.1542/neo.12-10-e575 . | Open in Read by QxMD
  34. Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics. 2015; 135 (2): p.e383-e391. doi: 10.1542/peds.2014-2377 . | Open in Read by QxMD
  35. Le T, Bhushan V,‎ Sochat M, Chavda Y, Zureick A. First Aid for the USMLE Step 1 2018. McGraw-Hill Medical ; 2017
  36. Katzung B,Trevor A. Basic and Clinical Pharmacology. McGraw-Hill Education ; 2014
  37. Kelly E. Efficacy and ligand bias at the μ-opioid receptor. Br J Pharmacol. 2013; 169 (7): p.1430-1446. doi: 10.1111/bph.12222 . | Open in Read by QxMD
  38. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012; 6 (1): p.11-16. doi: 10.1177/2049463712438493 . | Open in Read by QxMD